Immunotherapy of experimental melanoma with ICOS-Fc loaded in biocompatible and biodegradable nanoparticles.

Animals Immunity, Cellular Immunotherapy Inducible T-Cell Co-Stimulator Ligand Inducible T-Cell Co-Stimulator Protein Melanoma, Experimental / drug therapy Mice Nanoparticles Tumor Microenvironment
Controlled release ICOS-L Melanoma PLGA nanoparticles β-Cyclodextrin nanosponges

Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
10 04 2020
Historique:
received: 09 09 2019
revised: 15 01 2020
accepted: 17 01 2020
pubmed: 22 1 2020
medline: 22 6 2021
entrez: 22 1 2020
Statut: ppublish

Résumé

Inducible T-cell costimulator (ICOS) upon binding to its ligand (ICOSL) mediates adaptive immunity and antitumor response. Thus, antitumor therapies targeting the ICOS/ICOSL pathway hold great promise for cancer treatment. In this regard, ICOSL triggering by a soluble recombinant form of ICOS (ICOS-Fc) hampered adhesiveness and migration of dendritic, endothelial, and tumor cells in vitro. Furthermore, in vivo treatment with ICOS-Fc previously showed the capability to inhibit lung metastatization of ICOSL

Identifiants

DOI: 10.1016/j.jconrel.2020.01.030 PMID: 31962094
pubmed: 31962094
pii: S0168-3659(20)30049-3
doi: 10.1016/j.jconrel.2020.01.030
pii:
doi:

Substances chimiques

Icos protein, mouse 0
Inducible T-Cell Co-Stimulator Ligand 0
Inducible T-Cell Co-Stimulator Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112-124

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest A patent application has been submitted for use of ligands of ICOSL loaded in nanoparticles in tumors treatment.

Auteurs

Nausicaa Clemente (N)

Department of Health Sciences, Inter Interdisciplinary Research Center of Autoimmune Diseases, UPO, 28100 Novara, Italy.

Elena Boggio (E)

Department of Health Sciences, Inter Interdisciplinary Research Center of Autoimmune Diseases, UPO, 28100 Novara, Italy.

Luca Casimiro Gigliotti (LC)

Department of Health Sciences, Inter Interdisciplinary Research Center of Autoimmune Diseases, UPO, 28100 Novara, Italy.

Davide Raineri (D)

Department of Health Sciences, Inter Interdisciplinary Research Center of Autoimmune Diseases, UPO, 28100 Novara, Italy; Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del Piemonte Orientale, 28100 Novara, Italy.

Benedetta Ferrara (B)

Department of Scienza e Tecnologia del Farmaco, University of Torino, 10125 Torino, Italy.

Gianluca Miglio (G)

Department of Scienza e Tecnologia del Farmaco, University of Torino, 10125 Torino, Italy.

Monica Argenziano (M)

Department of Scienza e Tecnologia del Farmaco, University of Torino, 10125 Torino, Italy.

Annalisa Chiocchetti (A)

Department of Health Sciences, Inter Interdisciplinary Research Center of Autoimmune Diseases, UPO, 28100 Novara, Italy; Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del Piemonte Orientale, 28100 Novara, Italy.

Giuseppe Cappellano (G)

Department of Health Sciences, Inter Interdisciplinary Research Center of Autoimmune Diseases, UPO, 28100 Novara, Italy; Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del Piemonte Orientale, 28100 Novara, Italy.

Francesco Trotta (F)

Department of Chemistry, University of Torino, 10125 Torino, Italy.

Fabrizio Caldera (F)

Department of Chemistry, University of Torino, 10125 Torino, Italy.

Maria Teresa Capucchio (MT)

Department of Veterinary Sciences, University of Torino, 10095 Grugliasco, TO, Italy.

Junji Yagi (J)

Department of Microbiology and Immunology, Tokyo Women's Medical University, Tokyo 108-8639, Japan.

Maria Josè Rojo (MJ)

Departamento de Medicina Celular y Molecular, Centro de Investigaciones Biologicas, Consejo Superior de Investigaciones Cientıficas, 28040 Madrid, Spain.

Filippo Renò (F)

Department of Health Sciences, Inter Interdisciplinary Research Center of Autoimmune Diseases, UPO, 28100 Novara, Italy.

Roberta Cavalli (R)

Department of Scienza e Tecnologia del Farmaco, University of Torino, 10125 Torino, Italy. Electronic address: roberta.cavalli@unito.it.

Chiara Dianzani (C)

Department of Scienza e Tecnologia del Farmaco, University of Torino, 10125 Torino, Italy.

Umberto Dianzani (U)

Department of Health Sciences, Inter Interdisciplinary Research Center of Autoimmune Diseases, UPO, 28100 Novara, Italy; Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del Piemonte Orientale, 28100 Novara, Italy.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Immunotherapy of experimental melanoma with...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité cellulaire › Immunotherapy of experimental melanoma with...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Immunotherapy of experimental melanoma with...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Ligand de la protéine inductible de costimulation du lymphocyte T › Immunotherapy of experimental melanoma with...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Protéine inductible de costimulation du lymphocyte T › Immunotherapy of experimental melanoma with...
questionsmedicales.fr › Techniques d'investigation › Modèles animaux › Tumeurs expérimentales › Mélanome expérimental › Immunotherapy of experimental melanoma with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Immunotherapy of experimental melanoma with...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Immunotherapy of experimental melanoma with...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Immunotherapy of experimental melanoma with...